Concorde Asset Management LLC acquired a new position in Anixa Biosciences, Inc. (NASDAQ:ANIX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 13,969 shares of the company’s stock, valued at approximately $31,000.
Other institutional investors have also recently added to or reduced their stakes in the company. Staley Capital Advisers Inc. acquired a new position in Anixa Biosciences in the first quarter valued at approximately $31,000. Simplicity Wealth LLC acquired a new position in Anixa Biosciences in the first quarter valued at approximately $44,000. Nations Financial Group Inc. IA ADV lifted its stake in Anixa Biosciences by 50.0% in the second quarter. Nations Financial Group Inc. IA ADV now owns 22,500 shares of the company’s stock valued at $50,000 after buying an additional 7,500 shares during the period. Finally, Virtu Financial LLC lifted its stake in Anixa Biosciences by 47.2% in the first quarter. Virtu Financial LLC now owns 16,156 shares of the company’s stock valued at $50,000 after buying an additional 5,183 shares during the period. 29.13% of the stock is owned by institutional investors and hedge funds.
Insider Activity
In other news, Director Lewis H. Titterton, Jr. acquired 21,646 shares of the firm’s stock in a transaction dated Tuesday, July 30th. The stock was purchased at an average price of $3.06 per share, for a total transaction of $66,236.76. Following the completion of the acquisition, the director now directly owns 890,754 shares in the company, valued at approximately $2,725,707.24. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 22.60% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Research Report on ANIX
Anixa Biosciences Stock Down 0.9 %
NASDAQ ANIX opened at $3.42 on Friday. The company has a market cap of $109.46 million, a price-to-earnings ratio of -9.14 and a beta of 0.86. Anixa Biosciences, Inc. has a 52 week low of $2.14 and a 52 week high of $5.13. The business has a 50 day moving average price of $3.16 and a 200-day moving average price of $2.99.
Anixa Biosciences (NASDAQ:ANIX – Get Free Report) last released its quarterly earnings data on Friday, September 6th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01. On average, equities research analysts anticipate that Anixa Biosciences, Inc. will post -0.43 earnings per share for the current year.
About Anixa Biosciences
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.
Read More
- Five stocks we like better than Anixa Biosciences
- Compound Interest and Why It Matters When Investing
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- The 3 Best Retail Stocks to Shop for in August
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.